secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001193125-25-026156
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Founder Berns becomes CEO as Gosebruch departs; option repricing approved
-------------------------------------------------------------------------

- Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.
- CEO Henry Gosebruch and Chief Commercial Officer Kaya Pai Panandiker leave the company.
- Joshua Pinto promoted to president (base $645k, 60% target bonus, $970k signing bonus, 3M option).
- Bill Aurora becomes COO & CDO; Michael Milligan becomes CFO; other leadership changes announced.
- Board approved option repricing subject to stockholder approval; exercise price set at Feb 13 closing price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/0001193125-25-026156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525026156/d932957d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-026156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer